Herbalife 3rd Quarter 2026 Earnings Conference Call - HERBALIFE LTD

Explicit Guidance:

• Q4 2026 Reported Net Sales: Expected to increase 0.5% to 4.5% year-over-year, incorporating a 200 basis point currency headwind.
• Q4 2026 Constant Currency Net Sales: Expected to increase 2.5% to 6.5% year-over-year.
• Q4 2026 Adjusted EBITDA: Projected at $145 million to $165 million (reported) and $155 million to $175 million (constant currency).
• Q4 2026 Capital Expenditures (CapEx): Expected to range from $13 million to $23 million.
• Full Year 2026 Reported Net Sales: Raised to a 4.9% to 5.9% year-over-year increase.
• Full Year 2026 Constant Currency Net Sales: Raised to a 5.3% to 6.3% year-over-year increase.
• Full Year 2026 Adjusted EBITDA: Maintained at $670 million to $690 million (reported) and raised to $700 million to $720 million (constant currency).
• Full Year 2026 CapEx: Narrowed guidance to $55 million to $65 million.
• Full Year 2026 SaaS Implementation Costs: Capitalized and prepaid costs expected to range from $35 million to $45 million (incremental to CapEx).
• Full Year 2026 Effective Tax Rate: Expected to be approximately 35%.

Business-Segment Outlook:

• Nutrition Clubs: Goal to establish a dedicated internal organization to support the 64,000+ global clubs, focusing on tailored products, training, and tools to increase productivity and profitability; currently seeing >10% annual club productivity growth and >7% customer door growth.
• Customer Engagement Platform: Launching a common, modular technology foundation in Q1 2027 to replace disparate tools (Engage, Hub, Protocol), enabling distributors to create customizable digital programs; target to capture at least 50% of global distributor consumer transactions within the ecosystem over the next three years.
• Bionic Brand: Expanding from personalized nutrition into a premium health and wellness brand (sports performance, healthy lifespan) throughout 2027; plans to introduce additional personalized nutrition SKUs and more convenient formats; merging "Life.io" into the Bionic brand to create a unified sports and business opportunity platform.
• GLP-1 Related Products: Developing programs to position current product portfolio (protein, energy, teas) to coexist with and complement consumers using GLP-1 medications, rather than creating new products.
• India: Continuation of growth momentum expected in the fourth quarter as the company laps the third quarter 2025 GST change; India remains a primary growth driver.
• Skincare: Expansion of global reach for skincare offerings.

Market and Competitive Outlook:

• Human Connection: Leveraging social isolation trends (1 in 6 people globally, 50% of US adults) as a competitive advantage by scaling community-based experiences like the "24 Games" global rollout; first US event held in Miami with 350 attendees, planned for replication.
• Pricing & Mix: Pricing benefits are a key lever for margin; however, country mix and input costs (self-manufacturing/sourcing) remain headwinds to gross margins.
• Share Shifts: No specific market share targets mentioned, but strategy focuses on enabling distributor flexibility to capture transactions currently lost to "patchwork" outside apps and manual processes.

Macro / Industry Outlook:

• Foreign Exchange (FX): Anticipated to remain a headwind to net sales and EBITDA in Q4 2026 (projected 200 bps impact on reported sales).
• Input Costs: Monitoring input cost trends as a key variable for 2027 margin planning.
• Regulatory: Referenced the GST change in India (Q3 2025) as a past catalyst; no new regulatory risks cited beyond standard operational considerations.

Strategic Initiatives:

• Technology Foundation: Targeting Q1 2027 for the initial rollout of the new modular customer engagement platform, starting with the "24 Games" vertical, followed by challenges and nutrition club modules.
• M&A/Brand Integration: Full integration of "Life.io" into the "Bionic" brand structure to streamline operations and consumer appeal.
• Capital Allocation: Initiation of a $250 million share repurchase program in Q4 2026 to be executed systematically and opportunistically.
• Debt Management: Progress toward long-term objectives of ~$1.4 billion total debt and ~$1 billion net debt, maintaining net leverage ≤ 2.0x (achieved 2.0x at Q3 quarter-end); no significant debt maturities until 2028 convertible notes.
• Margin Strategy: Management intends to announce specific three-year margin objectives on the Q4 2026 earnings call, detailing prioritized levers for expansion.

Risks and Headwinds to Outlook:

• FX Volatility: Currency fluctuations remain a significant variable; Q3 saw a 160 bps headwind (vs. 100 bps expected), with a 200 bps headwind anticipated in Q4.
• Input Costs: Higher costs related to self-manufacturing, sourcing, and other operational expenses have pressured gross margins (-60 bps total in Q3).
• Country Mix: Unfavorable sales mix (primarily North America vs. higher-growth emerging markets) acted as a $47 million headwind in Q3.
• Platform Adoption Risk: Future value of the new technology platform depends on distributor usage ("usage decides value"); low current usage of "Protocol" and risk of slow adoption of new modules could impact execution.
• GLP-1 Coexistence: Uncertainty in consumer acceptance of current products when taken alongside GLP-1 medications.

Management Tone on the Future:

• Confidence: High confidence in the company's future, citing the "entrepreneurial spirit" of 3+ million distributors and the strength of the core business as a primary competitive moat.
• Strategic Focus: Shift from "building" to "leveraging"; leadership emphasizes execution, accountability, and a clear path to growth by supporting existing distributor models rather than reinventing them.
• Margin Outlook: Cautious optimism; while Q3 margins improved, management explicitly states the path to further expansion will be "more gradual" in Q4 2027 and beyond, with a disciplined focus on margin levers.
• Leadership: Interim CEO John DeSimone expresses strong belief in the platform's ability to scale and "deliver value" by enabling distributor innovation.

Miscellaneous:

• 24 Games: Described as a team-based fitness event scalable globally; intended to be the first module on the new customer engagement platform in Q1 2027.
• Capital Expenditure Structure: Clarified that SaaS implementation costs ($35M–$45M) are capitalized/prepaid and incremental to the CapEx budget ($55M–$65M).
• Refinancing Impact: Recent debt refinancing extended maturity profile and reduced net interest expense by $19 million year-over-year in Q3.